• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Targeting podoplanin for the treatment of osteosarcoma
CONCLUSIONS: Targeting PDPN with a neutralizing antibody against PDPN-CLEC-2 without ADCC and CDC is a novel therapeutic strategy for PDPN-positive OS.PMID:35381070 | DOI:10.1158/1078-0432.CCR-21-4509
Source: Clinical Cancer Research - April 5, 2022 Category: Cancer & Oncology Authors: Ai Takemoto Satoshi Takagi Takao Ukaji Nobuhiko Gyobu Mamoru Kakino Miho Takami Asami Kobayashi Marie Lebel Tokuichi Kawaguchi Minoru Sugawara Kazue Tsuji-Takayama Kenji Ichihara Yuki Funauchi Keisuke Ae Seiichi Matsumoto Yoshiya Sugiura Kengo Takeuchi Te Source Type: research

Identification of a Novel SYK/c-MYC/MALAT1 Signaling Pathway and Its Potential Therapeutic Value in Ewing Sarcoma.
CONCLUSIONS: The present study identifies a novel signaling involving SYK/c-MYC/MALAT1 as a promising therapeutic target for the treatment of EWS. PMID: 28336564 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - March 23, 2017 Category: Cancer & Oncology Authors: Sun H, Lin DC, Cao Q, Pang B, Gae DD, Lee VK, Lim HJ, Doan N, Said JW, Gery S, Chow M, Mayakonda A, Forscher C, Tyner JW, Koeffler HP Tags: Clin Cancer Res Source Type: research

Systematic screening identifies dual PI3K and mTOR inhibition as a conserved therapeutic vulnerability in osteosarcoma.
CONCLUSIONS: The approaches described here have identified dual inhibition of the PI3K/mTOR pathway as a sensitive, druggable target in OS and provide rationale for translational studies with these agents. PMID: 25862761 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - April 10, 2015 Category: Cancer & Oncology Authors: Gupte A, Baker E, Wan SS, Stewart E, Loh A, Shelat AA, Gould CM, Chalk A, Taylor S, Lackovic K, Karlstrom A, Mutsaers A, Desai J, Madhamshettiwar PB, Zannettino AC, Burns C, Huang DC, Dyer M, Simpson KJ, Walkley C Tags: Clin Cancer Res Source Type: research

Dual targeting of EWS-FLI1 activity and the associated DNA damage response with Trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
CONCLUSIONS: These results provide the basis and rationale for translating this drug combination to the clinic. In addition, the study highlights an approach that utilizes a targeted agent to interfere with an oncogenic transcription factor and then exploits the resulting changes in gene expression to develop a molecularly targeted combination therapy. PMID: 24277455 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - November 25, 2013 Category: Cancer & Oncology Authors: Grohar PJ, Segars LE, Yeung C, Pommier Y, D'Incalci M, Mendoza A, Helman LJ Tags: Clin Cancer Res Source Type: research